“Post-COVID Fatigue: Why It Happens and How to Recover”

This Is Not Ordinary Tiredness

Every person who has had COVID-19 feels tired afterward. That is normal. The kind of fatigue that defines post-COVID syndrome is something qualitatively different. Patients describe a bone-deep exhaustion that does not lift after sleep, that returns without any clear trigger, and that renders previously simple tasks, walking to the kitchen, holding a conversation, staring at a screen for more than a few minutes, genuinely impossible [1].

This distinction matters because the interventions that help normal post-illness fatigue, rest for a few days, eat well, get back to activity, can actually worsen post-COVID fatigue. The biology underlying these two presentations is different, and conflating them has caused real harm in clinical settings where patients were pushed to exercise their way back to health.

The Biology of Post-COVID Fatigue

Mitochondrial Dysfunction

Mitochondria generate the ATP that powers every cell in the body. SARS-CoV-2 disrupts mitochondrial function through several routes. Viral proteins interact directly with mitochondrial membranes. The infection triggers sustained oxidative stress that damages mitochondrial DNA. Inflammatory cytokines produced during and after infection inhibit mitochondrial respiratory chain complexes. The net result is a significant reduction in cellular energy production capacity that can persist long after the virus itself is gone [2].

Muscle biopsies from Long COVID patients with fatigue have revealed mitochondrial abnormalities including reduced complex I activity, impaired oxidative phosphorylation, and structural changes to mitochondria. These are not findings you can detect with a routine blood test, which is one reason patients are often told their results are normal when the real problem sits at the cellular level.

NAD+ Depletion

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial energy production and cellular repair. During COVID-19 infection, NAD+ is consumed at an accelerated rate by multiple processes. PARP enzymes, activated by viral damage to DNA, burn through NAD+ rapidly. CD38, an enzyme on immune cells that spikes during inflammation, also degrades NAD+ in large quantities [3].

The result is a state of NAD+ deficiency that may persist for months after acute illness. Low NAD+ impairs mitochondrial function, reduces cellular repair capacity, and disrupts sirtuin pathways involved in inflammation regulation and circadian rhythm. This creates a self-perpetuating cycle where cellular energy production stays low and repair processes are impaired.

Immune Activation and Neuroinflammation

Chronic immune activation is documented in Long COVID patients with fatigue. Elevated cytokines, particularly IL-6, TNF-alpha, and interferon signatures, are found in blood samples months after acute infection. Microglial activation, the brain’s resident immune cells shifting into an inflammatory state, has been identified in PET imaging studies of Long COVID patients and likely contributes directly to both fatigue and cognitive symptoms [4].

The sustained immune activation may reflect several things: viral persistence in tissue reservoirs, reactivation of latent viruses like Epstein-Barr virus (EBV), autoimmune processes triggered by molecular mimicry, or microbiome dysbiosis driving gut-derived immune signals. In many patients, more than one of these is active simultaneously.

Autonomic Dysfunction

Dysautonomia, disruption of the autonomic nervous system, contributes significantly to fatigue in Long COVID. The autonomic system regulates heart rate, blood pressure, circulation, and the distribution of blood to muscles and organs. In patients with POTS (postural orthostatic tachycardia syndrome) or related forms of dysautonomia, circulation becomes dysregulated in ways that impair oxygen delivery to tissues during any kind of activity.

Even without POTS, many Long COVID patients have blunted heart rate variability, impaired baroreflex function, and reduced blood flow to the brain in upright postures. These abnormalities manifest as fatigue and cognitive impairment that worsens when standing or exerting and improves somewhat when lying down [5].

Microclotting

Research from South African scientists Resia Pretorius and Douglas Kell has identified a specific type of microscopic fibrin clot in Long COVID blood samples that is resistant to normal fibrinolysis (clot breakdown). These microclots may impair capillary-level oxygen delivery even when larger vessels appear normal on standard imaging. The consequence would be a persistent tissue-level oxygen deficit that explains the effort intolerance many patients experience [6].

Post-Exertional Malaise: The Critical Distinction

Post-exertional malaise (PEM) is the feature that most clearly distinguishes ME/CFS-like Long COVID fatigue from other types. PEM is a disproportionate worsening of symptoms following physical or cognitive exertion. The crash is often delayed by 12 to 48 hours and can last from days to weeks. The threshold for triggering PEM can be surprisingly low, sometimes just a brief walk or a mentally demanding phone call.

Studies using cardiopulmonary exercise testing (CPET) have objectively documented PEM in Long COVID patients. When tested on two consecutive days, patients with PEM show a significant drop in aerobic capacity, oxygen efficiency, and anaerobic threshold on day two. Healthy controls and patients with deconditioning do not show this pattern. PEM is physiologically real and distinguishable [7].

This finding has enormous practical importance. It means that graded exercise therapy, the standard recommendation for general fatigue and deconditioning, is contraindicated for patients with PEM. Pushing through crashes makes patients worse. The British PACE trial, which promoted graded exercise for ME/CFS, has faced sustained scientific criticism, and Long COVID researchers have largely moved away from that approach.

Pacing: The Foundation of Management

Pacing means staying within your energy envelope at all times to avoid triggering PEM. The goal is not to do as little as possible, but to calibrate activity levels to what the body can currently sustain without crashing.

Heart rate monitoring is the most practical pacing tool available. Research suggests that exceeding the anaerobic threshold, approximately 50 to 60% of heart rate reserve, is when PEM risk increases substantially. Many patients use a formula-based threshold of around 110 to 115 beats per minute, though this varies by individual. Staying below this threshold during all activities, including cognitive work, social interaction, and emotional stress, prevents the crashes that derail recovery [8].

Pacing is not rest forever. It is a structured approach that gives the autonomic and immune systems space to stabilize while avoiding the repeated cycles of crash and recovery that can entrench the condition. Most patients find that with consistent pacing, their energy envelope gradually expands over months.

NAD+ Replenishment

Given the documented role of NAD+ depletion in post-COVID fatigue, replenishment strategies are a logical intervention. IV NAD+ therapy delivers the molecule directly into circulation at concentrations not achievable orally. Protocols used in Long COVID patients typically involve 500 to 1000mg infused slowly over 2 to 4 hours, with 3 to 10 sessions over several weeks [9].

Patient-reported outcomes from Long COVID clinics using IV NAD+ are consistently positive for energy levels and cognitive function. Controlled trial data is limited but building. The safety record is strong, with the main side effect being flushing and occasional nausea during infusion when given too rapidly.

Oral NAD+ precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), can support NAD+ levels at a lower intensity. Doses studied range from 250 to 1000mg per day. Response is more variable than IV delivery but they offer a practical option for ongoing support between IV sessions or for patients without IV access.

Hyperbaric Oxygen Therapy

HBOT’s ability to address multiple drivers of post-COVID fatigue simultaneously makes it one of the most compelling treatment options available. High-pressure oxygen environments enhance mitochondrial function, promote angiogenesis (new blood vessel formation), reduce neuroinflammation, and may help dissolve microclots. The 2022 randomized controlled trial from Israel found significant improvements in fatigue, energy, and functional capacity after 40 HBOT sessions [10].

Not every HBOT facility uses the protocol studied in trials (90-minute sessions at 2.0 atmospheres with 100% oxygen and intermittent air breaks). Protocols matter. Patients pursuing HBOT for Long COVID fatigue should seek facilities familiar with the published protocols rather than those primarily set up for wound healing, which use different parameters.

Low-Dose Naltrexone

LDN’s mechanism in Long COVID fatigue likely involves reduction of microglial activation and normalization of immune signaling. Microglia in an activated state consume metabolic resources and produce inflammatory mediators that impair neuronal function and contribute to the fatigue-cognition intersection. By modulating microglial activation, LDN may reduce the inflammatory burden that sustains symptoms [11].

Typical dosing starts low, 0.5 to 1.5mg, and titrates up slowly to 3 to 4.5mg over several weeks to minimize side effects, which are mainly vivid dreams and mild sleep disruption in the first few weeks. The cost is low through compounding pharmacies, typically $30 to $60 per month, and the risk profile is favorable.

Sleep Optimization

Post-COVID fatigue is often compounded by profound sleep disruption. Many Long COVID patients experience non-restorative sleep, meaning they sleep for sufficient hours but wake feeling unrefreshed. This likely reflects disrupted sleep architecture, with reduced slow-wave sleep and abnormal sleep stage cycling. The reasons include autonomic dysregulation, pain, and neuroinflammation affecting sleep-regulating circuits [12].

Addressing sleep quality is important both for direct fatigue relief and because slow-wave sleep is when glymphatic clearance (brain waste removal) occurs. Poor sleep impairs this system, potentially worsening neuroinflammation and cognitive symptoms. Targeted approaches include sleep hygiene, treatment of autonomic dysfunction, and in some cases, low-dose melatonin (not high-dose, which can disrupt natural patterns) or other sleep-supporting supplements.

Nutritional Support

Several micronutrients are relevant to mitochondrial function and energy metabolism in Long COVID. Coenzyme Q10 is synthesized in mitochondria and supports electron transport chain function; depletion is associated with fatigue and has been found in COVID patients. Magnesium is a cofactor for over 300 enzymatic reactions and is depleted by inflammation; deficiency impairs ATP synthesis directly. B vitamins, particularly B1, B2, B3 (which is also an NAD+ precursor), and B12, are central to energy metabolism [13].

Targeted supplementation with these nutrients, ideally guided by testing, provides substrate support for mitochondrial recovery. This is not a cure, but it removes nutritional bottlenecks that can delay recovery.

What to Avoid

Certain approaches are either unhelpful or actively harmful for post-COVID fatigue with PEM. Graded exercise therapy that ignores PEM will worsen symptoms. Pushing through fatigue with stimulants, caffeine, or forced activity depletes energy reserves and can trigger prolonged crashes. Prolonged strict rest without any activity also leads to deconditioning that compounds the underlying problem.

The goal is a middle path: structured, paced activity that stays within current capacity, combined with targeted biological interventions that address the underlying drivers of fatigue, not just its symptoms.

Recovery Expectations

Recovery from post-COVID fatigue is real and happens for many patients, but the timeline is measured in months to years rather than weeks. Data from Long COVID registries suggest that somewhere between 20 and 40% of patients show meaningful improvement within one year, with rates continuing to rise over two to three years. A subset of patients with severe ME/CFS-like presentations have longer recovery trajectories [14].

Predictors of better outcomes include milder initial Long COVID severity, earlier access to appropriate care, absence of severe PEM, and younger age. Predictors of slower recovery include significant autonomic dysfunction, high baseline symptom burden, and repeated infections that reset progress.

None of this is deterministic. Patients with very severe presentations have recovered substantially. The key is avoiding the interventions that entrench the condition, namely ignoring PEM, while actively pursuing the ones that address its biology.

Related Reading

• Long COVID Symptoms: The Complete Guide to Post-COVID Syndrome
• Long COVID Treatment: Evidence-Based Options and What Actually Helps
• Long COVID Recovery: Timeline, Strategies, and When to Seek Help
• NAD+ IV Therapy: What It Does and Who It Helps
• Hyperbaric Oxygen Therapy: Benefits, Risks, and What to Expect
• Fibromyalgia Treatment: What Works and What Does Not

References

1. Twomey R, DeMars J, Franklin K, et al. “Chronic Fatigue and Postexertional Malaise in People Living With Long COVID.” JAMA Intern Med. 2022;182(12):1325-1331. doi:10.1001/jamainternmed.2022.5110
2. Guntur VP, Nemkov T, de Boer E, et al. “Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC).” Metabolites. 2022;12(11):1026. doi:10.3390/metabo12111026
3. Bharadwaj S, Singh M, Bhatt S, et al. “SARS-CoV-2 and mitochondria: a short overview.” EXCLI J. 2022;21:1165-1174. doi:10.17179/excli2022-5240
4. Nath A. “Long-Haul COVID.” Neurology. 2020;95(13):559-560. doi:10.1212/WNL.0000000000010640
5. Johansson M, Ståhlberg M, Widholm M, et al. “Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome.” JACC Case Rep. 2021;3(4):573-580. doi:10.1016/j.jaccas.2021.01.009
6. Pretorius E, Venter C, Laubscher GJ, et al. “Prevalence of readily detected amyloid blood clots in unvaccinated, vaccinated and COVID-19 patients.” Cardiovasc Diabetol. 2021;20(1):172. doi:10.1186/s12933-021-01359-7
7. Davenport TE, Stevens SR, Stevens J, et al. “Chronotropic Intolerance: An Overlooked Determinant of Symptoms and Activity Limitation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?” Front Pediatr. 2019;7:82. doi:10.3389/fped.2019.00082
8. Barber L, Storm CK, Wood E, et al. “Using Heart Rate Monitoring to Identify Orthostatic Tachycardia in People With Post-Acute Sequelae of COVID-19.” Phys Ther. 2023;103(2):pzac168. doi:10.1093/ptj/pzac168
9. Minhas PS, Liu L, Moon PK, et al. “Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation.” Nat Immunol. 2019;20(1):50-63. doi:10.1038/s41590-018-0255-3
10. Efrati S, Ben-Jacob E, Reshef A, et al. “Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial.” Nat Commun. 2022;13(1):6940. doi:10.1038/s41467-022-34638-y
11. Younger J, Parkitny L, McLain D. “The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.” Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2
12. Pinto MD, Geovene Oliveira IG, de Medeiros Santos AC, et al. “Post-COVID Syndrome: Persistence of Symptoms After COVID-19 in Brazil.” Healthcare. 2022;10(6):1118. doi:10.3390/healthcare10061118
13. Roth W, Zadeh K, Vekariya R, et al. “Tryptophan Metabolism and Gut-Brain Homeostasis.” Int J Mol Sci. 2021;22(6):2973. doi:10.3390/ijms22062973
14. Tran VT, Porcher R, Pane I, Ravaud P. “Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort.” Nat Commun. 2022;13(1):1812. doi:10.1038/s41467-022-29513-z